Skip to main content
GutCited

Butyrate (Sodium/Calcium Butyrate) pour Crohn's Disease

C

Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbutyrate\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

En conclusion

Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.

Key Study Findings

Randomized Controlled Trial n=140 Double-blind
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study …
Dose: None vs: placebo plus conventional therapy Outcome: clinical disease activity and fecal calprotectin Effet: None p=0.013

Population: IBD patients (60 Crohn's disease, 80 ulcerative colitis)

In Vitro
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and …
Dose: Low-dose and high-dose NaB vs: DSS-induced IBD mice; 5-ASA control Outcome: IBD symptom alleviation and ferroptosis inhibition Effet: None None

Population: DSS-induced IBD murine model

In Vitro
Effects of Lactobacillus paracei JY062 Postbiotic on Intestinal Barrier, Immunity, and Gut Microbiota.
Dose: 5 mg/mL vs: LPS-treated cell models Outcome: Intestinal barrier function and gut microbiota Effet: None None

Population: Caco-2 cells, RAW264.7 macrophages, fecal fermentation

Other
Association of Inflammatory Factors and Calcium Metabolism With Arthritis in Patients With Inflammatory Bowel Disease: …
Dose: None vs: None Outcome: Causal associations IBD → arthritis subtypes (MR) Effet: OR=1.21 (IBD→AS); OR=1.18 (IBD→PsA) <0.001 (AS); 0.007 (PsA)

Population: Mendelian randomization study of IBD and arthritis

Observational Study n=212
Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology.
Dose: None vs: Healthy controls Outcome: CD-specific microbiome signatures (AUC 0.94) Effet: AUC 0.94 in external validation None

Population: Crohn's disease and ulcerative colitis patients

In Vitro
Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn's disease: A pilot …
Dose: None vs: Untreated Crohn's disease microbiota Outcome: Gut microbiome modulation and inflammation Effet: None None

Population: Crohn's disease fecal microbiota in SHIME model

Key Statistics

2

Études

200

Participants

Positive

C

Note

Referenced Papers

Langenbeck's archives of … 2025 3 citations
Current opinion in … 2019 5 citations
Current pharmaceutical design 2018 108 citations
Gastroenterology 2017 335 citations
Innate immunity 2017 13 citations
Alimentary pharmacology & … 2005 227 citations
Alimentary pharmacology & … 2003 179 citations
Current opinion in … 2001 45 citations
Current opinion in … 2000 21 citations
Diseases of the … 1998 26 citations
Digestive diseases (Basel, … 1993 29 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
150-600 mg/day sodium or calcium butyrate
ibdsupport:
300-600 mg three times daily (900-1,800 mg/day)
butyrateenema:
100 mM butyrate enema for distal UC (clinical setting only)

Limite supérieure : No established upper limit for oral supplements; most studies use 600-4,000 mg/day

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Positive 140
Low-dose and high-dose NaB -- Positive --
5 mg/mL -- Positive --
None -- Positive --
None -- Positive 212
None -- Positive --
None -- Negative --
None -- Mixed --

Moment optimal de prise : With meals; enteric-coated formulations recommended to reach the colon

Safety & Side Effects

Effets indésirables signalés

  • Unpleasant taste/odor (butyric acid has a strong rancid butter smell)
  • Mild GI discomfort (nausea, bloating)
  • Belching with butyric acid odor
  • Enteric-coated formulations reduce taste issues

Interactions connues

  • 5-ASA medications (mesalamine) — additive anti-inflammatory effect (potentially beneficial in IBD)
  • No significant adverse drug interactions known

Apport maximal tolérable : No established upper limit for oral supplements; most studies use 600-4,000 mg/day

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Butyrate (Sodium/Calcium Butyrate) help with Crohn's Disease?
Based on 2 studies with 200 participants, there is limited but promising evidence that Butyrate (Sodium/Calcium Butyrate) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much Butyrate (Sodium/Calcium Butyrate) should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 150-600 mg/day sodium or calcium butyrate. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Butyrate (Sodium/Calcium Butyrate)?
Reported side effects may include Unpleasant taste/odor (butyric acid has a strong rancid butter smell), Mild GI discomfort (nausea, bloating), Belching with butyric acid odor, Enteric-coated formulations reduce taste issues. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Butyrate (Sodium/Calcium Butyrate) and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

Related Evidence

Butyrate (Sodium/Calcium Butyrate) pour d'autres pathologies

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.